Steve Smith

Long experience from clinical development in oncology. Physician by training. Big heart for improving care for patients. Zero tolerance for politics in science.

[Steve Smith @IMiDs_elderly]

@KonLontos @RahulBanerjeeMD @BloodAdvances @NikhilMunshiMD The graphs do not measure triplet vs. doublet therapy (despite article claims). They show the large reduction in OS benefit in frail/old pts from len-therapy. This reduction is reduced by bortezomib. More than likely frail patients would have had the best OS data with only Vd.

[Steve Smith @IMiDs_elderly]

/29 While this can be seen as simple academic arguments, the fact that we from an evidence-based medicine point of view are harming pts make this an inexcusable tragedy. 🧵End

[Steve Smith @IMiDs_elderly]

As a follow-up to the other thread about suppressed OS data with IMiDs in elderly and how PFS does not act as an IMiD survival surrogate, it is worthwhile to reflect over what MM survival data we had when as a myeloma community. 🧵

[Steve Smith @IMiDs_elderly]

/28 We as members of the myeloma community including regulators have desperately tried to make up arguments why these three trials should not be interpreted scientifically.